These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22872428)

  • 1. Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients.
    Serikawa KA; Jacobsen S; Lundsgaard D; Fox BA; Hummelshoj L; Poulsen LK; Fleckner J; Frederiksen KS
    Mod Rheumatol; 2013 Jul; 23(4):729-40. PubMed ID: 22872428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.
    Wright HL; Thomas HB; Moots RJ; Edwards SW
    Rheumatology (Oxford); 2015 Jan; 54(1):188-93. PubMed ID: 25125592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
    Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.
    van Baarsen LG; Wijbrandts CA; Rustenburg F; Cantaert T; van der Pouw Kraan TC; Baeten DL; Dijkmans BA; Tak PP; Verweij CL
    Arthritis Res Ther; 2010; 12(1):R11. PubMed ID: 20096109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis.
    Yokoyama-Kokuryo W; Yamazaki H; Takeuchi T; Amano K; Kikuchi J; Kondo T; Nakamura S; Sakai R; Hirano F; Nanki T; Koike R; Harigai M
    Arthritis Res Ther; 2020 Mar; 22(1):46. PubMed ID: 32164778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.
    Cantaert T; van Baarsen LG; Wijbrandts CA; Thurlings RM; van de Sande MG; Bos C; van der Pouw Kraan TC; Verweij CL; Tak PP; Baeten DL
    Rheumatology (Oxford); 2010 Jan; 49(1):156-66. PubMed ID: 19933783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
    Hirota T; Suzuki T; Ogishima H; Hagiwara S; Ebe H; Takahashi H; Yokosawa M; Umeda N; Kondo Y; Tsuboi H; Matsumoto I; Sumida T
    Mod Rheumatol; 2016; 26(1):29-35. PubMed ID: 26140463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray.
    Sanayama Y; Ikeda K; Saito Y; Kagami S; Yamagata M; Furuta S; Kashiwakuma D; Iwamoto I; Umibe T; Nawata Y; Matsumura R; Sugiyama T; Sueishi M; Hiraguri M; Nonaka K; Ohara O; Nakajima H
    Arthritis Rheumatol; 2014 Jun; 66(6):1421-31. PubMed ID: 24591094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
    Iwata S; Nakayamada S; Fukuyo S; Kubo S; Yunoue N; Wang SP; Yoshikawa M; Saito K; Tanaka Y
    Arthritis Rheumatol; 2015 Jan; 67(1):63-73. PubMed ID: 25303149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of biologics in rheumatoid arthritis: where are we going?
    Pucino F; Harbus PT; Goldbach-Mansky R
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J; Krüger K
    Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.